Colorectal Cancer Screening (NQF 0034)

EMeasure Name Colorectal Cancer Screening EMeasure Id c796ebcb-b03e-4ed7-99b2-b706561456ef
Version number 1 Set Id da479703-3931-40a0-909f-936ef106b1f1
Available Date No information Measurement Period January 1, 20xx through December 31, 20xx
Measure Steward National Committee for Quality Assurance
Endorsed by National Quality Forum
Description The percentage of adults 50-75 years of age who had appropriate screening for colorectal cancer.
Copyright
© National Committee for Quality Assurance. All Rights Reserved
Measure scoring Proportion
Measure type Process
Stratification
None
Risk Adjustment
None
Data Aggregation
Rationale
 This measure assesses the percentage of patients in a specific age demographic who receive appropriate screening for colorectal cancer. Colorectal cancer is the third leading cause of cancer-related deaths in the United States for both men and women, and was expected to be the primary cause of 49,920 deaths in 2009. In 2009, there were 106,100 new cases of colon cancer and 40,870 new cases of rectal cancer. Screening decreases mortality rates by detecting cancerous formations in the early and most curable stage; as a result, the mortality rate has been dropping for more than 20 years because of early identification of polyps for removal prior to disease onset, as well as other colorectal cancers. Screening is also fiscally responsible, with studies showing cost-savings of $40,000 per life-year gained. This measure facilitates efforts toward early detection of colorectal cancer and acceleration of treatment upon diagnosis. 
Clinical Recommendation Statement
 The United States Preventive Services Task Force : 
[1]The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, sigmoidoscopy, or colonoscopy in adults, beginning at age 50 years and continuing until age 75 years (A recommendation). 
[2]The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of computed tomographic (CT) colonography and fecal DNA testing as screening modalities for colorectal cancer (I statement). 

The American Cancer Society, The American College of Radiology, and the U.S. Multi-Society Task Force on Colorectal Cancer: 
Tests that Detect Adenomatous Polyps and Cancer
[1]Colonoscopy (every 10 yrs) 
[2]Flexible sigmoidoscopy (every 5 yrs) 
[3]fecal occult blood tests (fecal occult blood test (FOBT)) (A) 
[4]Double contrast barium enema (DCBE) (every 5 yrs)
[5]Computed tomographic colonography (CTC) (every 5 years) 

Tests that Primarily Detect Cancer: 
[1]gfecal occult blood test (FOBT) with high sensitivity for cancer (annually) 
[2]FIT with high sensitivity for cancer (annually) 
[3]sDNA with high sensitivity for cancer (interval uncertain) 

Modalities not approved: 
[1]Single digital rectal examination fecal occult blood test (FOBT) has a poor sensitivity for CRC and should not be performed as a primary screening method (A) 
[2]Studies evaluating virtual colonoscopy and fecal DNA testing for CRC screening have yielded conflicting results and therefore cannot be recommended (A) 
Improvement notation
Higher score indicates better quality
Measurement duration
12 month(s)
Reference
Screening for Colorectal Cancer, Topic Page. October 2008. U.S. Preventive Services Task Force. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/uspstf/uspscolo.htm
Reference
Levin, B. MD, et al. Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A Joint Guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin 2008;58:00-00
Definition
Guidance

Table of Contents


Population criteria

Data criteria (QDS Data Elements)

Summary Calculation

Calculation is generic to all measures:



Measure set CLINICAL QUALITY MEASURE SET 2011-2012